Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Sep 04, 2022 8:46am
160 Views
Post# 34940667

RE:RE:RE:Now - look at Wallace's work related to western diets ...

RE:RE:RE:Now - look at Wallace's work related to western diets ...Correct - this is recent work.

Obviously 340 would required a redesign but that's in line with IBD and the new antiviral (ATB-344).  It would likely morph out of the learning that comes from those designs ... and ... it would likely come with 20 year IP.

But ... too much on the go ... I'm not looking for any quick move into 340 at this time.

------------------------

Too much underway with 346 and Phase 2.
Too much to do with IBD and antiviral.
Likely working on neuro-inflammation science now (latest work in Alzheimer's has me wondering if IBD and the antiviral will be tested in combination - and separately - when it comes to brain diseases)

Then - we could be into 340 (as per the funnel in the presentation).  I read it in clockwise fashion and assume that to be the order.  Best guess for now - don't have much else to go on.

Good Luck !

<< Previous
Bullboard Posts
Next >>